Remibrutinib Shows Reduced Relapse Rates in MS Phase III Trials

• Remibrutinib, a BTK inhibitor, reduced relapse rates more than teriflunomide in MS patients.
• The study involved twice daily oral doses of 100 mg of remibrutinib.
• Novartis' MS treatment showed a third less relapse rates compared to standard treatment.
• Remibrutinib has a cleaner safety profile compared to a rival drug from Roche.
• The efficacy of remibrutinib did not match the performance of Roche's drug.